The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
about
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewStatus of PI3K/Akt/mTOR pathway inhibitors in lymphomaA Pan-GTPase Inhibitor as a Molecular ProbePhase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesThe histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilizationConstitutive activation of the DNA damage response pathway as a novel therapeutic target in diffuse large B-cell lymphomaChallenges and perspective of drug repurposing strategies in early phase clinical trials.Combination of the deacetylase inhibitor panobinostat and the multi-kinase inhibitor sorafenib for the treatment of metastatic hepatocellular carcinoma - review of the underlying molecular mechanisms and first case report.Expression of Sirt1 and FoxP3 in classical Hodgkin lymphoma and tumor infiltrating lymphocytes: Implications for immune dysregulation, prognosis and potential therapeutic targeting.LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin/STAT3/Akt pathway.A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphomaNovel agents in Hodgkin lymphoma.Targeting oncogenic and epigenetic survival pathways in lymphoma.XIV. The rationale for combining targeted and biological anti-lymphoma drugs.Signaling pathways in lymphoma: pathogenesis and therapeutic targets.Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies.Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeletonPost-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.HDAC6 regulates sensitivity to cell death in response to stress and post-stress recoveryCarnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling.Expression and Regulation of the Endogenous Retrovirus 3 in Hodgkin's Lymphoma Cells.Post-autologous transplant maintenance therapies in lymphoma: current state and future directions.Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.Pharmacotherapeutic Management of Pediatric Lymphoma.Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.[Advances in the research of glycolysis and lung cancer].
P2860
Q26770716-D320B70A-67D2-44FC-85F1-03CE733FABEFQ27026544-7E066867-8BAB-4AB2-8F94-0A7926B3D160Q28547072-F93F2593-DE16-411D-9AD6-B4556F424998Q33410761-F886F5AE-F8F9-4DF0-AFBE-3AEC9EDEA75DQ33435113-EEC9FBC1-0907-469E-8C2C-3C4A6C6281C4Q33442755-FA03D227-5446-4646-B425-35B0C5D9AE78Q33886267-29CB7417-4FE4-4DA3-83A7-677C15B7E977Q35053177-D0037C45-D009-4639-89A7-FCDE210EE3DFQ35059923-E95CC413-634A-49EA-A1D8-08F139A1D761Q35740025-80116E4B-AA50-4A4E-BDBA-C26D2C213475Q35863063-0DF8687D-3329-4CE1-9008-7EA522C66489Q35895346-6E44F6BB-B171-4B84-BF4F-48E6342727A7Q36375393-B439AE02-B243-4041-8D9F-5A9A61AEEAE5Q37369888-B8466DE8-FB41-499A-94FD-B0757FB048BEQ37649637-31854612-8041-4954-9A51-2930B9F6C729Q38019429-9FE1A0AE-F081-4145-BD2D-91F8A3C3CBD8Q38084734-20DD5785-447A-40D9-9673-F1AAA6373E1AQ38115234-053B38C8-7229-41C5-84D1-0E73D20EA4A0Q38150876-E5B5101B-634E-46FF-8D82-C93BA84CEC60Q38179975-95472F58-A449-4F0B-BB61-1804646176C3Q38218128-5201A0A1-61AB-4D7D-A985-6A3923106C82Q38478630-108E62F4-BEAE-43DA-9923-701850120C9AQ38568358-8C2782D4-C4CD-4B8F-9110-CC7EB140EE17Q38635603-60BBF560-256D-4F37-89FF-5DAEF61B9ECAQ38906418-21CE284A-8EDC-480E-8467-AF482CE2843EQ39002935-01A8D4C2-7126-4D51-9B21-CA7986547B5AQ39147611-B73DC1DC-0387-44C3-80E9-085897DB8524Q39386056-CE13594A-7D3B-4765-8233-B13EB95F2A5EQ47886065-0A8436AB-A57C-41D5-9CCB-59F2BD614261Q48267384-D25DD73D-D18C-46E8-95A8-F309A434DC85Q48321203-29A5DD8E-45E2-4420-97B2-2D141C893D97Q50640068-A2030828-1EBF-4547-8D34-84FB3F8791AFQ55464273-B748C8A4-7634-4D44-99AC-C38530DE743F
P2860
The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@ast
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@en
type
label
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@ast
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@en
prefLabel
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@ast
The pan-deacetylase inhibitor ...... n Hodgkin lymphoma cell lines.
@en
P2093
P2860
P1433
P1476
The pan-deacetylase inhibitor ...... in Hodgkin lymphoma cell lines
@en
P2093
Anas Younes
Daniela Buglio
Jiexin Zhang
L Jeffrey Medeiros
Manuela Lemoine
R Eric Davis
P2860
P304
P356
10.1182/BLOOD-2011-01-331421
P407
P577
2012-03-09T00:00:00Z